ALSO NOTED: Osiris shares jump on therapy results; Genmab recruits patients for leukemia study; Biocompatibles to launch stem c

> The international relief agency Oxfam lays the decline in pharma's overall stock performance at the developing world's doorstep. Investors know that emerging markets are key to the industry's growth, and Big Pharma is doing a lousy job in those markets, the agency contends. Report

> Shares of Osiris Therapeutics jumped 15 percent yesterday after the developer announced that its adult stem cell therapy for osteoarthritis produced "clinically and statistically significant" results over the past year. Report

> Denmark's Genmab has recruited 132 patients for a pivotal study of ofatumumab (HuMax-CD20(R)) for the treatment of refractory chronic lymphocytic leukemia. Release

> Biocompatibles International has received a green light from German regulators to start a trial of its stem cell therapy for hemorrhagic stroke. Report

> Pfizer and Nigeria's settlement talks in the litigation over a meningitis drug trial have broken down, government attorneys said. Report

> Big happenings in FDA Advisory Panel land today: The pediatrics committee is looking at GlaxoSmithKline's asthma drugs Serevent and Advair, while another panel preps for a closer look at Abbott's proposed drug-coated stent, Xience. Report

> Connecticut's decision to funnel $100 million into embryonic stem cell research has fueled a host of research programs in the state. Report

> Scientists at the University of Oxford are preparing clinical trials to test a new way to treat kidney and liver tumors. Ultrasound waves will be directed to tumors, where bubbles will develop and pop, releasing heat and killing cancer cells. Report

And Finally... The anti-smoking drug Champix has been linked to suicidal feelings. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.